112 related articles for article (PubMed ID: 7507589)
1. Pharmacokinetics of oral decongestants.
Kanfer I; Dowse R; Vuma V
Pharmacotherapy; 1993; 13(6 Pt 2):116S-128S; discussion 143S-146S. PubMed ID: 7507589
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children.
Simons FE; Gu X; Watson WT; Simons KJ
J Pediatr; 1996 Nov; 129(5):729-34. PubMed ID: 8917241
[TBL] [Abstract][Full Text] [Related]
3. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse.
Eccles R
Br J Clin Pharmacol; 2007 Jan; 63(1):10-4. PubMed ID: 17116124
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a single dose of phenylpropanolamine following oral administration at two different times of the day.
Rao VV; Rambhau D; Rao BR; Srinivasu P
Arzneimittelforschung; 1998 Nov; 48(11):1087-90. PubMed ID: 9850430
[TBL] [Abstract][Full Text] [Related]
5. In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation.
Devane J; Mulligan S; Foynes M; Martin M
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():297-9. PubMed ID: 1820895
[TBL] [Abstract][Full Text] [Related]
6. Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine.
Erickson CH; McLeod RL; Mingo GG; Egan RW; Pedersen OF; Hey JA
Am J Rhinol; 2001; 15(2):83-90. PubMed ID: 11345158
[TBL] [Abstract][Full Text] [Related]
7. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
[TBL] [Abstract][Full Text] [Related]
9. Selecting a decongestant.
Hendeles L
Pharmacotherapy; 1993; 13(6 Pt 2):129S-134S; discussion 143S-146S. PubMed ID: 7507590
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions between phenylpropanolamine, caffeine and chlorpheniramine in rats.
Kaddoumi A; Nakashima MN; Wada M; Nakashima K
Eur J Pharm Sci; 2004 Jun; 22(2-3):209-16. PubMed ID: 15158906
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.
Csajka C; Haller CA; Benowitz NL; Verotta D
Br J Clin Pharmacol; 2005 Mar; 59(3):335-45. PubMed ID: 15752380
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of a controlled-release suspension of phenylpropanolamine in healthy volunteers].
Chen QC; Chen WL; Dai YQ; Ge GQ; Lin DC
Yao Xue Xue Bao; 1992; 27(4):299-302. PubMed ID: 1442046
[TBL] [Abstract][Full Text] [Related]
14. Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects.
Graf P; Toll K; Palm J; Hallén H
Acta Otolaryngol; 1999; 119(7):837-42. PubMed ID: 10687944
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
16. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet.
Shargel L; Silverman HI; Cohen P; Brisson J; Dennis S
Biopharm Drug Dispos; 1990 Oct; 11(7):569-83. PubMed ID: 2265237
[TBL] [Abstract][Full Text] [Related]
18. Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans.
Huupponen R; Karhuvaara S; Anttila M; Vuorilehto L; Scheinin H
Clin Pharmacol Ther; 1995 Nov; 58(5):506-11. PubMed ID: 7586944
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacology of the methamphetamine stereoisomers.
Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of multiple dosage bioavailability between phenylpropanolamine controlled release suspension and conventional tablet in healthy volunteers].
Shen YX; Xu CD; Gao XH; Lin DC; Liu GL
Yao Xue Xue Bao; 1995; 30(2):157-60. PubMed ID: 7785434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
